← 홈

PD-1 / PD-L1

77개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 77개
CGTBiologicstalejiuwei cuiPhase 1

PD-1-M1-NK Cells (PD-1-M1-NK Cells)

Advanced Gastric or Colorectal Cancer · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleZhongda HospitalPreclinical

PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab)

Hepatocellular Carcinoma · PD-1

#PD-1#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 ACTIVE
CGTBiologicstaleDaihong LiuPhase 2

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

Multiple Myeloma · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleZhejiang UniversityPhase 1

PD1-PSMA-CART cells (PD1-PSMA-CART cells)

Castrate-Resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

anti-PD-1 (Pembrolizumab, Pembrolizumab (anti-PD-1))

Unresectable Melanoma; Metastatic Melanoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses)

HNSCC; Oral Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses)

HNSCC; Oral Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
ADCBiologicstaleChanghai HospitalPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+PD-1+platinum-based)

Esophageal Squamous Carcinoma; HER-2 Protein Overexpression · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
CGTBiologicstaleLiang PengPhase 1

Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib (Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib)

Advanced/Metastatic Hepatocellular Carcinoma · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
AntibodystaleInnoventPhase 2

PD-1 inhibitor (Sintilimab, Sintilimab (PD-1 inhibitor))

Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Tucidinostat (Tucidinostat, Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, chidamide)

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
CGTBiologicstaleShanghai Cell Therapy Research …Phase 2

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Advanced Solid Tumor · EGFR

#EGFR#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodyBiologicstaleEli LillyPhase 3

pembrolizumab (Keytruda, cetuximab+PD-1 mAb, Pembrolizumab/Finotonlimab, cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy)

Squamous Cell Carcinoma of Head and Neck · PD-1

#PD-1#Antibody#Phase3#항체#면역항체+3
효능 ORR 0%임상시험 1상태 RECRUITING
AntibodystaleChinese PLA General HospitalPhase 2

oxaliplatin+capecitabine+bevacizumab+PD-1 antibody (oxaliplatin+capecitabine+bevacizumab+PD-1 antibody)

Colorectal Cancer; RAS Mutation · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

anti-PD-1 monoclonal antibody (pembrolizumab, pembrolizumab (anti-PD-1 monoclonal antibody))

Solid Tumor · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleShanghai Cancer Hospital, ChinaPhase 2

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
CGTBiologicstaleSichuan UniversityPhase 1

BHP01 (α-PD-L1/4-1BB DLL3 CAR-T, α-PD-L1/4-1BB DLL3 CAR-T (BHP01))

Small Cell Lung Cancer Extensive Stage · PD-L1

#PD-L1#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING

4 / 4 페이지

← 이전다음 →